PMID- 28810946
OWN - NLM
STAT- MEDLINE
DCOM- 20171222
LR  - 20181023
IS  - 1482-1826 (Electronic)
IS  - 1482-1826 (Linking)
VI  - 20
IP  - 0
DP  - 2017
TI  - Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A 
      Meta-Analysis of Randomised Controlled Trials.
PG  - 285-294
LID - 10.18433/J3Q35D [doi]
AB  - We aimed to comprehensively analyse the safety and efficiency of rotigotine for 
      treating Parkinson's disease (PD). We conducted systematic literature searches of 
      Cochrane library, PubMed and Embase databases up to April 2016, with 
      'Rotigotine', 'Parkinson Disease ' and 'Parkinson's disease' as key searching 
      terms. Outcomes, including Unified Parkinson's Disease Rating Scale (UPDRS) Part 
      III and Part II scores, 'off' time, adverse events (AEs), serious AEs and 
      discontinuation because of AEs, were compared between rotigotine and placebo 
      groups under a fixed or random effect model. For dichotomous and continuous data, 
      risk ratio (RR) and weighted mean difference with their corresponding 95% 
      confidence intervals (95% CIs) were taken as the effect sizes to calculate merged 
      results. Twelve eligible studies were included. For patients with early or 
      advanced PD, rotigotine could significantly improve UPDRS Part III and Part II 
      scores (p < 0.001) and it had significantly higher incidence of AEs than the 
      placebo (p < 0.001). Regarding discontinuation because of AEs, rotigotine showed 
      a significant advantage over placebo in patients with early PD, whereas the 
      overall result demonstrated no statistically significant difference between the 
      groups. Rotigotine can improve daily living and motor ability of patients with 
      PD, although it has higher incidence of AEs. Rotigotine might be more appropriate 
      for patients with advanced PD than for those with early PD. This article is open 
      to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by 
      clicking on ABSTRACT on the issue's contents page.
FAU - Chen, Fei
AU  - Chen F
AD  - Department of Neurology, Shanghai Tongji Hospital, Tongji University School of 
      Medicine, Shanghai 200065, China.
FAU - Jin, Lingjing
AU  - Jin L
FAU - Nie, Zhiyu
AU  - Nie Z
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - Switzerland
TA  - J Pharm Pharm Sci
JT  - Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian 
      Society for Pharmaceutical Sciences, Societe canadienne des sciences 
      pharmaceutiques
JID - 9807281
RN  - 0 (Tetrahydronaphthalenes)
RN  - 0 (Thiophenes)
RN  - 87T4T8BO2E (rotigotine)
SB  - IM
MH  - Humans
MH  - Parkinson Disease/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Tetrahydronaphthalenes/administration & dosage/adverse effects/*therapeutic use
MH  - Thiophenes/administration & dosage/adverse effects/*therapeutic use
EDAT- 2017/08/16 06:00
MHDA- 2017/12/23 06:00
CRDT- 2017/08/17 06:00
PHST- 2017/08/17 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/12/23 06:00 [medline]
AID - 10.18433/J3Q35D [doi]
PST - ppublish
SO  - J Pharm Pharm Sci. 2017;20(0):285-294. doi: 10.18433/J3Q35D.